Glucagon administration decreases hepatic nuclear triiodothyronine binding capacity.
The maximal binding capacity (MBC) of nuclear triiodothyronine (T3) receptor sites in rat liver decreases markedly after glucagon administration. Administration of serial doses of glucagon (2.5 microgram/100 g BW) resulted in a 33% decrease in MBC in 3.5 h and MBC was reduced by 45% in 6.25 h. The individual doses used were in the same order of magnitude as those used in the treatment of hypoglycemic human subjects (1.5 microgram/100 g BW). This report presents the first evidence that a peptide hormone can change the number of nuclear T3 receptor sites. The physiological significance of these findings remains to be clarified.
D000818:Animals; D002467:Cell Nucleus / Q000378:metabolism; D005934:Glucagon / Q000494:pharmacology*; D008099:Liver / Q000378:metabolism* / Q000648:ultrastructure; D008297:Male; D051381:Rats; D011956:Receptors, Cell Surface / Q000187:drug effects* / Q000378:metabolism; D014284:Triiodothyronine / Q000378:metabolism*
D011956:Receptors, Cell Surface; D014284:Triiodothyronine; D005934:Glucagon